They found that Creld2 is regulated by PERK-modulated ATF4 via a putative C/ebp-Atf response element (CARE) in the promoter sequences of Creld2, and CRELD2 depletion suppresses tumor progression, indicating that the paracrine ROCK-PERK-ATF4-CRELD2 axis promotes breast cancer progression. The gene discussed is CRELD2; the disease is breast carcinoma.